LENALIDOMIDE DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Lenalidomide Drug Market, By Application (Multiple myeloma, Transfusion-dependent anemia, and Mantle cell lymphoma, and Others), By Strength (10 mg, 20 mg, 25 mg, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and NATCO Pharma Limited, a pharmaceutical company, announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules) in the U.S., including 2.5 mg and 20 mg strengths
In September 2022, Lotus Pharmaceutical, a multinational pharmaceutical company, announced the launch of lenalidomide Capsules (generic version of Revlimid) in the U.S. in strengths of 5mg, 10mg, 15mg, and 25mg
In September 2022, Zydus Lifesciences Limited, a pharmaceutical company, announced that it had received the U.S. Food and Drug Administration (FDA) approval to market Lenalidomide Capsules, USP 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The company has gained final clearances for 5 mg, 10 mg, 15 mg, and 25 mg strengths, as well as preliminary approvals for 2.5 mg and 20 mg strength.
In September 2022, Cipla Limited, an India-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted final approval for its Abbreviated New Drug Application (ANDA) for lenalidomide Capsule 5 mg, 10 mg, 15 mg, and 25 mg

Lenalidomide Drug Market Report Snapshots